A combination of genetic tests for a "very complex" blood cancer could accurately predict if the disease is likely to return ...

Eligible patients in Scotland with relapsed or refractory multiple myeloma will now have access to a new treatment option ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) negativity rates, compared with the control arm, in patients with relapsed ...

Researchers sought to determine whether elranatamab would lead to durable responses in patients with relapsed or refractory multiple myeloma.

Novel therapies for certain autoimmune diseases have been developed to end B cell-driven immune attacks on normal tissues.

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...

A study carried out by a team of researchers from The Institute of Cancer Research, London, found that combining two types of ...

A quote shared during our bi-weekly Tuesday multiple myeloma support group, where five or more gather in the virtual Zoom ...

The drug belantamab mafodotin – also known as Blenrep – has been approved for use for patients with myeloma, when used ...

It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie ...